Verily Broadens Clinical Research Offerings with SignalPath Buyout
Verily has announced that it is on track to acquire SignalPath, a Raleigh, N.C.-based company that provides a digital clinical trial management system (CTMS) for study sites.
SignalPath’s CTMS features a dedicated team of protocol digitizers that evaluate trial protocols, convert them into digital copies and perform protocol checks alongside sites to improve efficiency and quality. Once digitized, protocols can then be tracked and managed within the system.
Verily, which now employs former FDA principal deputy commissioner Amy Abernethy as its president of clinical studies platforms, said the deal will serve to expand its own trial system and evidence generation platform, Baseline.